Literature DB >> 11545290

Testicular pathology in 46,XY dysgenetic male pseudohermaphroditism: an approach to pathogenesis of testis cancer.

J Słowikowska-Hilczer1, M Szarras-Czapnik, K Kula.   

Abstract

Eleven children with dysgenic male pseudohermaphroditism (DMP) and 18 boys with isolated penile hypospadias, all with 46,XY karyotype, were studied. Testicular dysgenesis was associated with significantly lower testosterone response to human chorionic gonadotropin (0.9 +/- 0.2 ng/mL) than it was in hypospadias (3.3 +/- 0.1 ng/mL), and with significantly higher mean serum follicle-stimulating hormone (FSH) levels (8.4 +/- 2.3 IU/L vs 1.5 +/- 0.3 IU/L). Gonadoblastoma, a tumor that arises from the sex cords, was found in more than 1/4 of patients with DMP, whereas testicular carcinoma in situ (CIS) cells were present in all of these patients. Forty-two percent to 98% of CIS cells revealed an aneuploid pattern of nuclear DNA, indicating that most of them are neoplastic cells. In patients with hypospadias, CIS was not seen, and no other abnormalities were detected. In children with DMP, the percentage of tubules populated with germ cells was significantly lower than it was in those with hypospadias (48.3% +/- 10.6% vs 92.4% +/- 4.0%). The total number of germ cells (CIS cells + spermatogonia) did not differ significantly between the 2 groups, but the number of spermatogonia was significantly reduced in children with DMP (0.08 +/- 0.05 vs 3.65 +/- 0.2), suggesting impaired differentiation of gonocytes to spermatogonia. The following significant correlations were present with DMP: 1) the higher the seminiferous tubule cross-section area, the higher the number of CIS cells (r = 0.78); and 2) the higher the serum gonadotropin levels, the higher were tubular diameter (r = 0.93 for FSH and r = 0.75 for luteinizing hormone [LH]), area (r = 0.79 for FSH and r = 0.82 for LH), percentage of tubules populated with germ cells (r = 0.86 for FSH and r = 0.81 for LH), and number of CIS cells (r = 0.87 for FSH and r = 0.79 for LH). The results indicate that in intersex children with 46,XY karyotype, CIS occurs in dysgenetic testes in all cases and is frequently associated with gonadoblastoma. Impaired organogenesis of sex cords, relative inhibition of testosterone secretion, and the associated increased secretion of gonadotropins may create a milieu that induces or is favorable for the formation or maintenance of neoplastic lesions in dysgenetic testes early in childhood.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11545290

Source DB:  PubMed          Journal:  J Androl        ISSN: 0196-3635


  6 in total

1.  46XY Disorder of Sexual Development in Menstrual Dysfunction.

Authors:  Jayaben S Charania; Vidya V Salaskar
Journal:  J Obstet Gynaecol India       Date:  2012-10-16

2.  Intratubular germ cell neoplasms of the testis and bilateral testicular tumors: clinical significance and management options.

Authors:  Michael C Risk; Timothy A Masterson
Journal:  Indian J Urol       Date:  2010 Jan-Mar

Review 3.  Endocrine-disrupting chemicals: an Endocrine Society scientific statement.

Authors:  Evanthia Diamanti-Kandarakis; Jean-Pierre Bourguignon; Linda C Giudice; Russ Hauser; Gail S Prins; Ana M Soto; R Thomas Zoeller; Andrea C Gore
Journal:  Endocr Rev       Date:  2009-06       Impact factor: 19.871

4.  Testicular cancer in androgen insensitivity syndrome in a Mexican population.

Authors:  José Aguilar-Ponce; Fátima Chilaca Rosas; Carlos Molina Calzada; Martín Granados García; Miguel Angel Jiménez Ríos; Jaime De la Garza Salazar
Journal:  Clin Transl Oncol       Date:  2008-12       Impact factor: 3.405

5.  Long-Term Follow-Up of Patients with 46,XY Partial Gonadal Dysgenesis Reared as Males.

Authors:  Juliana Gabriel Ribeiro de Andrade; Antonia Paula Marques-de-Faria; Helena Campos Fabbri; Maricilda Palandi de Mello; Gil Guerra-Júnior; Andréa Trevas Maciel-Guerra
Journal:  Int J Endocrinol       Date:  2014-12-14       Impact factor: 3.257

Review 6.  Malignancy in disorders of sex development.

Authors:  Martin Kathrins; Thomas F Kolon
Journal:  Transl Androl Urol       Date:  2016-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.